
    
      Radiotherapy scheduling and prescription dose does not take into account individual patient
      heterogeneity in normal tissue response or tumour response. Personalisation of radiotherapy
      dose based on real-time assessments of normal tissue and tumour response would maximise cure
      and minimise treatment related toxicity. During a 5 fraction course of prostate Stereotactic
      Body Radiotherapy (SBRT) this pilot study will assess whether a number of different biomarker
      approaches can predict for normal tissue and tumour response. Firstly the investigators will
      analyse volatile organic compounds released within the breath with each fraction of treatment
      using Gas Chromatography Ion Mobility Spectroscopy (GC-IMS). The investigators have extensive
      experience in this area within the TOXI-Triage research program (www.toxi-triage.eu/)
      including deep learning and machine learning techniques to interrogate the metabolomics data
      generated. Secondly the investigators will analyse cell free normal tissue and tumour DNA
      released during treatment to assess both tumour and normal tissue response. Radiotherapy
      releases large amounts in to the blood stream allowing easier quantitative analysis. Thirdly
      the investigators will look for imaging biomarkers of rectal wall toxicity using imaging
      analysis algorithms of on-treatment cone beam verification CT images taken before and after
      each radiotherapy treatment. The RayPilotÂ® system made by Micropos Medical Ltd tracks
      prostate motion throughout the SBRT delivery to ensure that the treatment dose is delivered
      with great precision. The potential of each biomarker approach for predicting normal tissue
      and tumour response will be assessed against PSA and CTCAE v 4.0 toxicity criteria and
      EPIC-26 patient reported outcome measures after 24 months of patient follow up.
    
  